Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
FDF
0
FDA Orange Book
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 4-(6-bromoveratryl)-4-(2-(2-(6,6-dimethyl-2-norpinyl)ethoxy)ethyl)morpholinium Bromide
2. Dicetel
3. Eldicet
4. Pinaverium
1. 53251-94-8
2. Dicetel
3. Pinaverium Bromide [inn]
4. Lat-1717
5. Pinaverium Bromide (inn)
6. Morpholinium, 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethylbicyclo[3.1.1]hept-2-yl)ethoxy]ethyl]-, Bromide (1:1)
7. Pinaverii Bromidum
8. 4-(2-bromo-4,5-dimethoxybenzyl)-4-(2-(2-(6,6-dimethylbicyclo[3.1.1]heptan-2-yl)ethoxy)ethyl)morpholin-4-ium Bromide
9. Bromuro De Pinaverio
10. Bromure De Pinaverium
11. Lat 1717
12. Pinaverii Bromidum [inn-latin]
13. Bromure De Pinaverium [inn-french]
14. Bromuro De Pinaverio [inn-spanish]
15. 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethyl-2-bicyclo[3.1.1]heptanyl)ethoxy]ethyl]morpholin-4-ium;bromide
16. 4-(6-bromoveratryl)-4-(2-(2-(6,6-dimethyl-2-norpinyl)ethoxy)ethyl)morpholinium Bromide
17. Ncgc00181763-01
18. Einecs 258-450-0
19. 7scf54h12j
20. Unii-7scf54h12j
21. Pinaveriumbromide-d4
22. Dsstox_cid_28540
23. Dsstox_rid_82812
24. Dsstox_gsid_48614
25. Schembl25474
26. Morpholinium, 4-(2-bromo-4,5-dimethoxy)benzyl-4-(2-(2-(6,6-dimethyl-2-norpinyl)ethoxy)ethyl)-, Bromide
27. Chembl1909298
28. Dtxsid2048614
29. 4-[(2-bromo-4,5-dimethoxy-phenyl)methyl]-4-[2-[2-[(1s,5s)-6,6-dimethylnorpinan-2-yl]ethoxy]ethyl]morpholin-4-ium Bromide
30. Bcp21168
31. Tox21_112949
32. Mfcd01713435
33. Akos015918115
34. Gs-6842
35. 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethylbicyclo[3.1.1]-hept-2-yl)ethoxy]ethyl]morpholinium Bromide
36. Cas-53251-94-8
37. Hy-111613
38. Cs-0088569
39. Ft-0673906
40. P2753
41. D07094
42. Lat 1717; Lat-1717; Lat1717
43. A870784
44. Q27268790
45. 4-(2-bromo-4,5-dimethoxybenzyl)-4-{2-[2-(6,6-dimethylbicyclo[3.1.1]hept-2-yl)ethoxy]ethyl}morpholin-4-ium Bromide
46. 4-[(2-bromo-4,5-dimethoxy-phenyl)methyl]-4-[2-[2-(6,6-dimethylnorpinan-2-yl)ethoxy]ethyl]-1-oxa-4-azoniacyclohexane Bromide
47. 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-(2-{6,6-dimethylbicyclo[3.1.1]heptan-2-yl}ethoxy)ethyl]morpholin-4-ium Bromide
48. Morpholinium,4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethylbicyclo[3.1.1]hept-2-yl)ethoxy]ethyl]-, Bromide
| Molecular Weight | 591.4 g/mol |
|---|---|
| Molecular Formula | C26H41Br2NO4 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 10 |
| Exact Mass | 591.13818 g/mol |
| Monoisotopic Mass | 589.14023 g/mol |
| Topological Polar Surface Area | 36.9 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 596 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 3 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Calcium Channel Blockers
A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)
Parasympatholytics
Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)
API SUPPLIERS
M2i Group, an integrated CDMO, is your French partner for development & manufacturing in fine chemistry.
Registrant Name : Ilyang Pharmaceutical Co., Ltd.
Registration Date : 2021-03-17
Registration Number : 20210317-209-J-889
Manufacturer Name : M2I SALIN
Manufacturer Address : route d'Arles, SALIN DE GIRAUD, 13129, France
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21990
Submission : 2008-09-26
Status : Active
Type : II
Date of Issue : 2022-09-01
Valid Till : 2024-11-04
Written Confirmation Number : WC-0092
Address of the Firm :
NDC Package Code : 65372-1135
Start Marketing Date : 2008-09-29
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Date of Issue : 2022-09-19
Valid Till : 2025-07-02
Written Confirmation Number : WC-0119
Address of the Firm :
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Market Place
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
